Cargando…

Activatable molecular agents for cancer theranostics

Theranostics that integrates diagnosis and treatment modalities has attracted great attention due to its abilities of personalized therapy and real-time monitoring of therapeutic outcome. Such a theranostic paradigm requires agents to simultaneously possess the capabilities of targeting, imaging, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jianjian, Ning, Lulu, Huang, Jiaguo, Zhang, Chi, Pu, Kanyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145638/
https://www.ncbi.nlm.nih.gov/pubmed/34123034
http://dx.doi.org/10.1039/c9sc05460j
_version_ 1783697221313626112
author Zhang, Jianjian
Ning, Lulu
Huang, Jiaguo
Zhang, Chi
Pu, Kanyi
author_facet Zhang, Jianjian
Ning, Lulu
Huang, Jiaguo
Zhang, Chi
Pu, Kanyi
author_sort Zhang, Jianjian
collection PubMed
description Theranostics that integrates diagnosis and treatment modalities has attracted great attention due to its abilities of personalized therapy and real-time monitoring of therapeutic outcome. Such a theranostic paradigm requires agents to simultaneously possess the capabilities of targeting, imaging, and treatment. Activatable molecular agents (AMAs) are promising for cancer theranostics, as they show a higher signal-to-noise ratio (SNR), real-time detection of cancer-associated biomarkers, lower normal tissue toxicity, and a higher therapeutic effect. This perspective summarizes the recent advancements of AMAs, which include imaging-guided chemotherapy, imaging-guided photodynamic therapy, and imaging-guided photothermal therapy. The molecular design principles, theranostic mechanisms, and biomedical applications of AMAs are described, followed by a discussion of potential challenges of AMAs in cancer theranostics.
format Online
Article
Text
id pubmed-8145638
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-81456382021-06-11 Activatable molecular agents for cancer theranostics Zhang, Jianjian Ning, Lulu Huang, Jiaguo Zhang, Chi Pu, Kanyi Chem Sci Chemistry Theranostics that integrates diagnosis and treatment modalities has attracted great attention due to its abilities of personalized therapy and real-time monitoring of therapeutic outcome. Such a theranostic paradigm requires agents to simultaneously possess the capabilities of targeting, imaging, and treatment. Activatable molecular agents (AMAs) are promising for cancer theranostics, as they show a higher signal-to-noise ratio (SNR), real-time detection of cancer-associated biomarkers, lower normal tissue toxicity, and a higher therapeutic effect. This perspective summarizes the recent advancements of AMAs, which include imaging-guided chemotherapy, imaging-guided photodynamic therapy, and imaging-guided photothermal therapy. The molecular design principles, theranostic mechanisms, and biomedical applications of AMAs are described, followed by a discussion of potential challenges of AMAs in cancer theranostics. The Royal Society of Chemistry 2019-11-22 /pmc/articles/PMC8145638/ /pubmed/34123034 http://dx.doi.org/10.1039/c9sc05460j Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Zhang, Jianjian
Ning, Lulu
Huang, Jiaguo
Zhang, Chi
Pu, Kanyi
Activatable molecular agents for cancer theranostics
title Activatable molecular agents for cancer theranostics
title_full Activatable molecular agents for cancer theranostics
title_fullStr Activatable molecular agents for cancer theranostics
title_full_unstemmed Activatable molecular agents for cancer theranostics
title_short Activatable molecular agents for cancer theranostics
title_sort activatable molecular agents for cancer theranostics
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145638/
https://www.ncbi.nlm.nih.gov/pubmed/34123034
http://dx.doi.org/10.1039/c9sc05460j
work_keys_str_mv AT zhangjianjian activatablemolecularagentsforcancertheranostics
AT ninglulu activatablemolecularagentsforcancertheranostics
AT huangjiaguo activatablemolecularagentsforcancertheranostics
AT zhangchi activatablemolecularagentsforcancertheranostics
AT pukanyi activatablemolecularagentsforcancertheranostics